Frontline Acalabrutinib Plus Chemoimmunotherapy Elicits Meaningful Survival Benefit in MCL
Acalabrutinib plus bendamustine and rituximab (BR) led to a statistically significant improvement in PFS vs BR for treatment-naive mantle cell lymphoma.
Stay updated with breaking news from Michael Wang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Acalabrutinib plus bendamustine and rituximab (BR) led to a statistically significant improvement in PFS vs BR for treatment-naive mantle cell lymphoma.
Adding Calquence to standard-of-care chemoimmunotherapy improved progression-free survival in patients with previously untreated mantle cell lymphoma.
30.04.2024 - Amprius Technologies, Inc. (“Amprius” or the “Company”) (NYSE: AMPX), a leader in next-generation lithium-ion batteries with its Silicon Anode Platform, hosted the Amprius Battery Forum in Taipei City, Taiwan on Tuesday, April 23, 2024. The forum, ...
/PRNewswire/ -- Ispire Technology Inc. (NASDAQ: ISPR) ("Ispire" or the "Company"), an innovator in vaping technology and precision dosing, announced it has...
Shaun Deeb is in for 13 bullets in the Texas Poker Open Main Event, meaning he'll need at least 8th place just to turn a profit out of the 735-player field.